P249 Physicians' opinion: ceilings of therapy in chronic obstructive pulmonary disease (PILOT study)

Statins and Pulmonary Hypertension in Chronic Obstructive Lung Disease

Chronic obstructive lung disease (COPD) is a chronic multisystem disease with a considerable burden. One of its most common complications is pulmonary artery hypertension (PAH). It has been demonstrated that the development of PAH is correlated with decreased quality of life and survival. Different medications have been proposed for the treatment of PAH, among which one can name statins. Howeve...

Aspergillus colonization in patients with chronic obstructive pulmonary disease

Background and Purpose: Chronic obstructive pulmonary disease (COPD) has been recognized as a risk factor for invasive aspergillosis. Airway colonization by Aspergillus species is a common feature of chronic pulmonary diseases. Nowadays, the incidence of COPD has increased in critically ill patients. The aim of the present study was to isolate and identify Aspergillus colonies in the respirator...

Effect of Pulmonary Rehabilitation Program on Severity of Symptoms in Patients with Chronic Obstructive Pulmonary Disease

800x600 Background and Objectives: Cough and dyspnea are two most common symptoms in chronic obstructive pulmonary disease patients. The aim of this study was to investigate the effect of pulmonary rehabilitation program on severity of symptoms in patients with chronic obstructive pulmonary disease. Materials and Methods: This study was a clinical trial in which 70 patien...

Pneumocystis jirovecii colonization in Chronic Obstructive Pulmonary Disease (COPD)

Chronic obstructive pulmonary disease (COPD) is associated with a chronic inflammatory response in airways and lung parenchyma that results in significant morbidity and mortality worldwide. Cigarette smoking considered as an important risk factor plays a role in pathogenesis of disease. Pneumocystis jirovecii is an atypical opportunistic fungus that causes pneumonia in immunosuppressed host, al...

chronic obstructive pulmonary disease: the gold or random therapy?